知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.017 seconds)

    Inhibition of APC-mediated apoptosis of activated T lymphocytes
    3.
    发明授权
    Inhibition of APC-mediated apoptosis of activated T lymphocytes 失效
    抑制APC介导的活化T淋巴细胞凋亡

    公开(公告)号：US5843635A

    公开(公告)日：1998-12-01

    申请号：US395149

    申请日：1995-02-27

    Applicant: Stuart F. Schlossman ,  Mei X. Wu

    Inventor： Stuart F. Schlossman ,  Mei X. Wu

    IPC: C07K16/28 ,  G01N33/50 ,  C12Q1/70 ,  C07K16/00 ,  G01N33/564

    CPC classification number: C07K16/28 ,  G01N33/505 ,  G01N2510/00

    Abstract: Methods for interfering with antigen presenting cell-mediated priming of resting peripheral blood T lymphocytes to undergo activation induced cell death ("apoptosis") by inhibiting an interaction between a membrane associated molecule ("an APC apoptotic ligand") present on stimulated antigen presenting cells ("APC") and a counter-receptor that is present on T lymphocytes are disclosed. The antigen presenting cells are preferably from the monocyte/macrophage cell line or are dendritic cells. Also disclosed are methods of screening for inhibitors of APC-mediated priming of T lymphocytes to undergo apoptosis and methods and agents for detecting, identifying and characterizing an APC apoptotic ligand. Inhibitors identified by the screening method of the invention are used to reduce the T lymphocyte depletion associated with HIV infection and thereby mitigate the severe immunodeficiency associated with AIDS by interfering with the association between HIV-infected antigen presenting cells, especially monocytes and macrophages, and T cells.

    Abstract translation: 用于通过抑制存在于受刺激的抗原呈递细胞上的膜相关分子（“APC凋亡配体”）之间的相互作用来干扰静息外周血T淋巴细胞的抗原呈递细胞介导的引发以激活诱导的细胞死亡（“凋亡”）的方法 （“APC”）和存在于T淋巴细胞上的反式受体。 抗原呈递细胞优选来自单核细胞/巨噬细胞细胞系，或者是树突状细胞。 还公开了筛选APC介导的T淋巴细胞引发抑制剂以进行凋亡的方法，以及用于检测，鉴定和表征APC凋亡配体的方法和试剂。 通过本发明的筛选方法鉴定的抑制剂用于减少与HIV感染相关的T淋巴细胞消耗，从而通过干扰HIV感染的抗原呈递细胞，特别是单核细胞和巨噬细胞之间的关联以及T降低与AIDS相关的严重免疫缺陷 细胞。

    Siva genes, novel genes involved in CD27-mediated apoptosis
    5.
    发明授权
    Siva genes, novel genes involved in CD27-mediated apoptosis 失效
    Siva基因，涉及CD27介导的凋亡的新基因

    公开(公告)号：US6010853A

    公开(公告)日：2000-01-04

    申请号：US865297

    申请日：1997-05-29

    Applicant: Prasad V. S. Kanteti ,  Zhaohui Ao ,  Stuart F. Schlossman

    Inventor： Prasad V. S. Kanteti ,  Zhaohui Ao ,  Stuart F. Schlossman

    IPC: A61K38/00 ,  C07K14/47 ,  C12N15/12 ,  C12Q1/68 ,  C07H21/04 ,  C12N15/85 ,  C12P19/34

    CPC classification number: C07K14/4705 ,  A01K2217/05 ,  A61K38/00 ,  C07K2319/00

    Abstract: The invention provides isolated nucleic acids molecules, designated Siva nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Siva nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Siva gene has been introduced or disrupted. The invention still further provides isolated Siva proteins, fusion proteins, antigenic peptides and anti-Siva antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

    Abstract translation: 本发明提供分离的核酸分子，命名为Siva核酸分子，其编码参与免疫细胞凋亡的蛋白质。 本发明还提供反义核酸分子，含有Siva核酸分子的重组表达载体，已导入表达载体的宿主细胞，以及Siva基因导入或破坏的非人类转基因动物。 本发明还进一步提供了分离的Siva蛋白，融合蛋白，抗原肽和抗Siva抗体。 还提供了利用本发明组合物的诊断，筛选和治疗方法。

    Monoclonal antibody which inhibits the adhesion functions of the .beta. integrin, CR3
    6.
    发明授权
    Monoclonal antibody which inhibits the adhesion functions of the .beta. integrin, CR3 失效
    抑制β整联蛋白CR3的粘附功能的单克隆抗体

    公开(公告)号：US5219997A

    公开(公告)日：1993-06-15

    申请号：US703941

    申请日：1991-05-22

    Applicant: Stuart F. Schlossman ,  James D. Griffin

    Inventor： Stuart F. Schlossman ,  James D. Griffin

    IPC: C07K16/28 ,  C12P21/08

    CPC classification number: C07K16/2845

    Abstract: A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.

    Abstract translation: 开发了杂交细胞系，其产生结合在吞噬细胞表面上表达的独特抗原位点的单克隆抗体。 单克隆抗体结合并激活CD11b糖蛋白的特异性结构域，以抑制吞噬细胞的粘附依赖性功能，但不影响其他吞噬功能。 该单克隆抗体可用作体外诊断免疫测定中的反应物，用于检测正常人嗜中性粒细胞表面上的独特抗原位点。

    Monoclonal antibody which distinguishes helper inducer and suppressor inducer CD4+ lymphocytes
    7.
    发明授权
    Monoclonal antibody which distinguishes helper inducer and suppressor inducer CD4+ lymphocytes 失效
    治疗呼吸窘迫综合征和抑制因子CD4 +淋巴细胞的单克隆抗体

    公开(公告)号：US5120642A

    公开(公告)日：1992-06-09

    申请号：US442062

    申请日：1989-11-28

    Applicant: Stuart F. Schlossman ,  Chikao Morimoto

    Inventor： Stuart F. Schlossman ,  Chikao Morimoto

    IPC: A61K39/395 ,  A61K38/00 ,  A61K49/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C07K19/00 ,  C12N5/10 ,  C12N5/20 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577

    CPC classification number: C07K16/28 ,  A61K38/00 ,  Y10S435/948 ,  Y10S530/809

    Abstract: A monoclonal antibody which binds preferentially to a subset of the human CD4+ lymphocyte population whereby to positively and precisely distinguish between helper-inducer and suppressor-inducer cells in the CD4+ cell population. The monoclonal antibody recognizes a novel antigen on the CD4+ lymphocytes by means of which it can bind CD4+ cells which express the antigen on the surface of CD4+ cells. The CD4+ subset cell population to which this antibody preferentially binds is the CD4+ helper-inducer population. This selectivity of the monoclonal antibody enables cell sorting, diagnostic and possible therapeutic applications thereof to be realized. The monoclonal antibody also reacts with CD8 cells, B cells and macrophages.

    Abstract translation: 一种单克隆抗体，其优先结合人CD4 +淋巴细胞群体的子集，从而正确和准确地区分CD4 +细胞群体中的辅助诱导物和抑制诱导物细胞。 单克隆抗体识别CD4 +淋巴细胞上的新抗原，通过它可以结合在CD4 +细胞表面表达抗原的CD4 +细胞。 该抗体优先结合的CD4 +亚群细胞群是CD4 +辅助诱导剂群体。 单克隆抗体的这种选择性使得能够实现细胞分选，诊断和可能的治疗应用。 单克隆抗体也与CD8细胞，B细胞和巨噬细胞反应。

    Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
    8.
    发明授权
    Method of reducing tissue damage at an inflammatory site using a monoclonal antibody 失效
    使用单克隆抗体减少炎性部位的组织损伤的方法

    公开(公告)号：US4840793A

    公开(公告)日：1989-06-20

    申请号：US61336

    申请日：1987-06-11

    Applicant: Robert F. Todd, III ,  Benedict R. Lucchesi ,  Paul J. Simpson ,  James D. Griffin ,  Stuart F. Schlossman

    Inventor： Robert F. Todd, III ,  Benedict R. Lucchesi ,  Paul J. Simpson ,  James D. Griffin ,  Stuart F. Schlossman

    IPC: A61K38/00 ,  C07K16/28

    CPC classification number: C07K16/2845 ,  A61K38/00 ,  Y10S530/806 ,  Y10S530/868

    Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.

    Abstract translation: 使用单克隆抗体减少人或其他动物物种组织损伤以抑制特定吞噬细胞功能的方法。 选择单克隆抗体以结合吞噬白细胞以抑制向体内炎症部位的迁移，并抑制到达该区域的活化白细胞的粘附和扩散，然后阻止这些细胞释放有毒物质。 单克隆抗体在导致有害炎症反应的经验过程中或之前在体内施用，例如可以由由急性冠状动脉血栓形成中断的心肌血流的恢复引起。

    Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof
    10.
    发明授权
    Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof 失效
    在人血清，抗体中发现的二肽基肽酶IV（CD26）的形式及其用途

    公开(公告)号：US06265551B1

    公开(公告)日：2001-07-24

    申请号：US08657339

    申请日：1996-06-03

    Applicant: Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

    Inventor： Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

    IPC: C07K1600

    CPC classification number: G01N33/573 ,  A61K38/00 ,  C07K16/40 ,  C12N9/48 ,  Y10S435/975

    Abstract: A circulating, soluble form of DPPIV/CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the ubiquitous membrane form. However, in several biochemical aspects there are distinct differences. In particular, the circulating serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the circulating form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Circulating DPPIV has been determined to be the soluble form of a 175 kDa DPPIV CD26-related molecule rapidly expressed on the surface of activated T cells, prior to the expression of 105 kDa CD26. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from 105 kDa CD26/DPPIV. Polyclonal and monoclonal antibodies capable of distinguishing the 175 kDa form from the 105 kDa form are also disclosed.

    Abstract translation: 公开了从人血清中分离的循环的可溶形式的DPPIV / CD26。 血清形式与普遍存在的膜形式具有相似的酶和抗原性质。 然而，在几个生化方面有明显的差异。 特别地，循环血清形式的分子量为175kDa（与膜形式的105kDa分子量相反），并且不结合腺苷脱氨酶1型。 然而，循环形式表达功能性二肽基肽酶IV活性，并保留共同刺激T淋巴细胞回忆抗原的能力。 循环DPPIV已被确定为在表达105kDa CD26之前在激活的T细胞表面上快速表达的175kDa DPPIV CD26相关分子的可溶形式。 尽管可以少量在血清中发现105kDa膜型CD26，但大部分血清DPPIV活性由与105kDa CD26 / DPPIV结构不同的新型肽酶提供。 还公开了能够区分175kDa形式与105kDa形式的多克隆和单克隆抗体。

Patent Agency Ranking